2nd Non-Opioid Pain Therapeutics Summit 2027

 

One year after JOURNAVX® became the first new class of pain medicine approved in decades, momentum across the non-opioid pain landscape continues to accelerate, driving significant scientific, clinical, and investment activity.

The 2nd Non-Opioid Pain Therapeutics Summit will unite leaders in pain biology, drug discovery, translational science, clinical development, medical affairs, and business development to examine how emerging mechanisms can be translated into effective therapies across acute and chronic pain indications.

Discussions will focus on human-relevant translational models, target and biomarker validation, clinical trial optimization, placebo response mitigation, and identifying investable assets.

Experts from Vertex Pharmaceuticals, Eli Lilly, AbbVie, Grünenthal, Xenon Pharmaceuticals, and NIH will share insights shaping the next generation of non-opioid therapeutics.

 

More Info

---

---